Merck & Co., Inc.
145.27USD
-1.9700 (-1.34%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on MRK.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16,607 | 16,286 | 16,400 | 17,276 | 15,806 | 15,529 | 15,624 | 16,657 |
| Cost of Revenue | 4,395 | 4,195 | 5,551 | 3,855 | 3,557 | 3,419 | 3,828 | 4,080 |
| Gross Profit | 12,212 | 12,091 | 10,849 | 13,421 | 12,249 | 12,110 | 11,796 | 12,577 |
| Operating Income | — | — | — | — | — | — | — | — |
| Net Income | -1,335 | -4,240 | 2,963 | 5,785 | 4,427 | 5,079 | 3,743 | 3,157 |
| EPS (Diluted) | -$0.54 | -$1.72 | $1.20 | $2.32 | $1.76 | $2.01 | $1.48 | $1.24 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)